eHealth Institute, Linnaeus University, Kalmar, Sweden.
J Clin Pharm Ther. 2012 Dec;37(6):686-92. doi: 10.1111/jcpt.12001. Epub 2012 Aug 28.
Interventions involving medication reconciliation and review by clinical pharmacists can reduce drug-related problems and improve therapeutic outcomes. The objective of this study was to examine the impact of routine admission medication reconciliation and inpatient medication review on emergency department (ED) revisits after discharge. Secondary outcomes included the combined rate of post-discharge hospital revisits or death.
This prospective, controlled study included all patients hospitalized in three internal medicine wards in a university hospital, between 1 January 2006 and 31 May 2008. Medication reconciliation on admission and inpatient medication review, conducted by clinical pharmacists in a multiprofessional team, were implemented in these wards at different times during 2007 and 2008 (intervention periods). A discharge medication reconciliation was undertaken in all the study wards, during both control and intervention periods. Patients were included in the intervention group (n = 1216) if they attended a ward with medication reconciliation and review, whether they had received the intervention or not. Control patients (n = 2758) attended the wards before implementation of the intervention.
No impact of medication reconciliation and reviews on ED revisits [hazard ratio (HR), 0.95; 95% confidence interval (CI), 0.86-1.04]or event-free survival (HR, 0.96; 95% CI, 0.88-1.04) was demonstrated. In the intervention group, 594 patients (48.8%) visited the ED, compared with 1416 (51.3%) control patients. In total, 716 intervention (58.9%) and 1688 (61.2%) control patients experienced any event (ED visit, hospitalization or death). Because the time to a subsequent ED visit was longer for the control as well as the intervention groups in 2007 than in 2006 (P < 0.05), we re-examined this cohort of patients; the proportion of patients revisiting the ED was similar in both groups in 2007 (P = 0.608).
Routine implementation of medication reconciliation and reviews on admission and during the hospital stay did not appear to have any impact on ED revisits, re-hospitalizations or mortality over 6-month follow-up.
涉及药物重整和临床药师审查的干预措施可以减少与药物相关的问题并改善治疗效果。本研究的目的是检验常规入院药物重整和住院药物审查对出院后急诊科(ED)复诊的影响。次要结果包括出院后医院复诊或死亡的综合率。
本前瞻性对照研究纳入了 2006 年 1 月至 2008 年 5 月期间在一家大学医院的三个内科病房住院的所有患者。在 2007 年和 2008 年期间(干预期间),临床药师在多专业团队中对入院时的药物重整和住院药物审查进行干预。在所有研究病房中均进行出院时的药物重整,包括对照和干预期。如果患者在接受药物重整和审查的病房就诊,则将其纳入干预组(n=1216),无论是否接受了干预。对照组患者(n=2758)在实施干预前在病房就诊。
未发现药物重整和审查对 ED 复诊(危险比[HR],0.95;95%置信区间[CI],0.86-1.04)或无事件生存(HR,0.96;95%CI,0.88-1.04)有影响。在干预组中,有 594 名患者(48.8%)就诊于急诊科,而对照组有 1416 名患者(51.3%)。共有 716 名干预组(58.9%)和 1688 名对照组(61.2%)患者发生任何事件(急诊科就诊、住院或死亡)。由于 2007 年对照组和干预组患者随后就诊于急诊科的时间均长于 2006 年(P<0.05),因此我们重新检查了该队列患者;2007 年两组患者的 ED 复诊比例相似(P=0.608)。
常规实施入院和住院期间的药物重整和审查似乎对 6 个月随访期间的 ED 复诊、再次住院或死亡率没有任何影响。